

가

I.

가 (marker)
 osteocalcin, osteonectin,
 collagen type - C propeptide ,
 pyridinolin,
 deoxypyridinolin 10)

1). 가 가
 30 - 40 가 가
 가 가
 가 가
 2,3). 가 가
 가 가
 4) 가 가
 가 가
 5). 가 가
 DEXA(dual energy X - ray absorp -
 tiometry) 가 (trace element)
 16), 가
 6,7). 가 가
 가 가
 17,18). 가 99%

* 1995

가 -70 Defreezer
2Mℓ
(TISAB III) 0.2Mℓ 가
(Orion Co., U.S.A.)

19 - 21)

가

(2)

22)

가

가

dual energy X - ray absorptiom -
etry (DEXA)

23,24)

(LUNAR - 3 Lunar Co., U.S.A)

2

4

25)

가

가

calcium , phosphorus , alkaline
phosphatase , hemoglobin

가

(3)

2

II.

periodontal probe(William probe, HuFriedy,
U.S.A.) (plaque index),

1.

(gingival index)

6

(attachment level)

28 (, 60.7 ± 4.9)

(panoramic view)

21 (, 38.8)

가 ,

± 5.4)

3

가

2.

3.

(1)

10

Table 1. Comparison of general conditions between postmenopausal and control group

| | postmenopausal(n=28) | control(n=21) |
|------------|----------------------|---------------|
| Age | 60.7 ± 4.9 | 38.8 ± 5.4 |
| Height(cm) | 152 ± 4.5 | 155 ± 3.8 |
| Weight(kg) | 57.8 ± 5.6 | 55.6 ± 4.8 |
| Obesity(%) | 105.5 ± 9.8 | 103.5 ± 6.6 |
| ALP* | 99.5 ± 18.8 | 101.5 ± 13.4 |
| FI# | 0.46 ± 0.34 | 0.37 ± 0.29 |

Values are mean ± SD, ALP*: alkaline phosphatase level in serum(U/L)

FI#: urinary fluoride concentration(mg/)




Figure 1. The mean urinary fluoride concentration in postmenopausal and control group

student t - test

III.

1.

28
60.7 38.8
21 152 cm, 57.8 kg, 105.5% 155
cm, 55.6 kg, 103.5% calcium
phosphorus , alkaline phosphatase
hemoglobin 16.5




Figure 2. Lumbar spine bone mineral density of postmenopausal and control group

Table 2. Comparison of oral conditions between postmenopausal and control group

| | postmenopausal(n=28) | |
|-------------------------------|-------------------------|--------------|
| | control(n=21) | |
| number of teeth | 16.5 ± 2.9 [†] | 21.9 ± 3.8 |
| means of PD [†] (mm) | 3.01 ± 0.31 | 2.72 ± 0.34* |
| means of AL [‡] (mm) | 3.38 ± 0.38 | 3.14 ± 0.26* |
| percent of BOP (%) | 42.3 ± 10.8 | 39.9 ± 13.1 |

Values are mean ± SD * :p<0.05

PD[†]: probing depth, AL[‡]: Attachment level, BOP : Bleeding on probing

(Table 1).

0.46 ± 0.34 mg/ , 0.37 ± 0.29 mg/

(Table 1,

Figure 1).

2

4

0.82 ± 0.11 g/cm², 0.96 ± 0.19 g/cm²

가

(p<0.05, Figure 2).

2.

glucocorticoid

8)

가

, Colles

32)

가

15)

가

가

가 15)

가

33).

가

dual energy X - ray absorptiometry (DEXA)

von Wowern 31)

가가 가

6,7).

가 22)

osteocalcin,

tyridinoline,

가

deoxypyridinoline

가

가

5,34,35)

가

36,37)

23,24,39)

가

가

가

11 - 14)

von Wowern 31)

Mohammad 38)

가

24,40)

3

가

SPADNS 41)

3.01 ± 0.31mm, 3.38 ± 0.38mm,
2.72 ± 0.34mm, 3.14 ± 0.26 mm

가

가 100 Mℓ 가 .

1966 Frant Ross⁴²⁾ 가 가 .

40) 가 가 .

0.37mg/ , 0.46 mg/ 가 Yoshida 가 가 .
43) 가 가 가

가 가 IV.
Yoshida 가

43) clearance () 28
野原⁴⁴⁾ () 21
가

가 1.
가 2.
가 3.
가 가
($p < 0.001$ = -0.526).

4. 가 , 가
5. 가 , 가 (marker)가 가

VI.

1. Lindsay R: Osteoporosis. A guide to diagnosis, prevention, and treatment. Raven press New York 8 - 33, 1992 .
2. 井上哲郎; 骨粗 症の診断基準. 整形外科 43: 1099 - 1105, 1992.
3. 白木正孝: 骨粗 症 新しい 診断法. 内科 76: 821 - 827, 1995.
4. Gorden GS: Drug treatment of the osteoporosis Annu Rev Pharmacol Toxicol 18;253 - 268, 1978.
5. Brown JP Delmas PD: Serum bone Gla - protein a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1091 - 1096, 1984.
6. 山田陸司: DXAによる骨鹽定量の現状と将来展望, 第 1 版 メティカルヒュ - 社, 東京 1995, 14 - 19.
7. 福永仁夫: DXAによる骨鹽定量の意義と問題點. 第 1 版 メティカルヒュ - 社, 東京, 1995, 22 - 29.
8. Reid IR Veale AG France JT : Glucocorticoid osteoporosis. J Asthma 31: 7 - 18, 1994.
9. Delmas PD: Biochemical markers of

- bone turnover for the clinical assessment of metabolic disease. Endocrine J Metab clinics North America 19: 1 - 18, 1990.
10. Ohishi T et al : Age related changes of urinary pyridinolin and deoxypyridinolin in Japanese women. The XIth International Conference on Calcium regulating hormones. Florence, Italy, April 24 - 29, 1992.
11. Gron JJ Menczel J Shapiro S: Chronic destructive periodontal disease in the patients with presenile osteoporosis. J Periodontal 39: 19 - 23, 1968.
12. Ward VJ and Manson JD: Alveolar bone loss in periodontal disease and the metacarpal index. J periodontal 44: 763 - 769, 1973.
13. Klemetti E Collin H - L Fross H Markkanen H Lassila V: Mineral status of skeleton and advanced periodontal disease. J Clin Periodontol 21; 184 - 188, 1994.
14. Solt DB: The pathogenesis, oral manifestations, and implications for dentistry of metabolic bone disease. Curr Opin Dent 1: 783 - 791, 1991.
15. : 29; 41 - 50, 1999.
16. Morita M: Trace Elements and Living Organism - Their Essentiality and Toxicity. 日本化学會譯. 丸善, 東京 369 - 371, 1975.
17. Churchill HV Lantz EM Smith HV: The cause of mottled enamel. J Dent Res 12; 149 - 160, 1932.
18. Hodge HC and Smith FA: Fluorine chemistry 4, Academic press, New York,

- 1965.
19. Orcel PH Verejoul MC Prier A Miravet L Kuntz D Kaplan G: Stress fractures of the lower limbs in osteoporosis promotes a progressive increase in spinal bone density. *J Bone Mineral Research* 5: 37 - 43, 1990.
 20. Søgarrd CH Mosekilde LI Richards A Mosekilde L: Marked decrease in trabecular bone quality after five years of sodium fluoride therapy - Assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients. *Bone* 15 :393 - 399, 1994.
 21. Yamamoto G Kagami S Kimura T Yoshitake K: Effects of fluoride on osteoporosis. *Osteoporosis Japan* 4 : 82 - 85, 1996.
 22. Modrowski D Miravet L Feuga M Banni F marie PJ: Effect of fluoride on bone and bone cells in ovariectomized rats. *J Bone Mineral Research* 7 : 961 - 969, 1992.
 23. Parkins FM Tinanoff N Mountinko M Anstey MB Waziri MH: Relationship of human plasma fluoride and bone fluoride to age. *Calcif Tiss Res* 16: 335 - 338, 1974.
 24. Nakaminami K and Niwa M: Effects of dietary fluoride and age of fluoride concentration in hard tissue in rats. *J Dent Health* 36;36 - 46, 1986.
 25. Inagaki K Fujishiro H Ohshima Y Suzuki H Asai Y Nagira T Murase M Yoshinari N Poblete MGS Noguchi T Kumazaki E Nagao T Mori C Hayakawa J Yamada K Hachiya Y: Periodontal and osteoporotic conditions in postmenopausal women. *Aich - Gakuin Dent Sci* 9: 33 - 40, 1996.
 26. Anderson JJB Gramer SC Mar MH: The ovariectomized, lactating rat as an experimental model for osteopenia : calcium metabolism and bone changes. *Bone Miner* 11: 43 - 53, 1990.
 27. Hayashi T Yamamuro T Okumura H et al : Effect of (Asu^{1.7}) - eel calcitonin on the prevention of osteoporosis induced by combination of immobilization and ovariectomy in the rat. *Bone* 10: 25 - 35, 1989.
 28. Calvo MS Harstad L Laakso KJ

- Health H: Chronic low calcium, high phosphorous intake during adolescence causes secondary hyperparathyroidism and reduces bone mass in female beagles. *J Bone Mineral Res* 2: S464, 1987.
29. Holick KF Krane S Potts JR : Calcium, phosphorus, and bone metabolism : calcium regulating hormones, In : Isswlbacher KJ, Braunwald E, Wilson LD, eds. *Harrison's Principles of Internal Medicine*, 13th ed. New York : McGraw - Hill, 2137 - 2151, 1994.
 30. Cook SD Skinner HB Haddad RJ: A quantitative histologic study of osteoporosis produced by nutritional secondary hyperparathyroidism in dogs. *Clin Orthop* 175: 105 - 110, 1983.
 31. von Wowern N Klausen B Kollerup G. : Osteoporosis : A risk factor in periodontal disease. *J Periodontol* 65: 1134 - 1138, 1994.
 32. Wactawski - Wende J Grossi SG Trevisan M Genco RJ Tezal M Dunford RG Ho AW Hausmann E Hreshchyshyn MM: The role of osteopenia in oral bone loss and periodontal disease. *J Periodontol* 67: 1076 - 1084, 1996.
 33. 楸野 浩: 骨粗 症の疫學. *整形外科* 43: 1027 - 1032, 1992.
 34. Fujimoto D Moriguchi T Ishida T: The structure of pyridinoine, a collagen crosslink. *Biochem Biophys Res commum* 84: 52 - 57, 1978.
 35. Ogawa T Ono T Tsud M: A novel fluor in insoluble collagen. *Biochem Biophys Res Commum* 107: 1252 - 1257, 1982.
 36. Fleish H: Bisphosphonates - history and experimental basis. *Bone* 8: 22 - 28, 1987.
 37. Fleish H: Bisphosphonates, a new class of drugs in diseases of bone and calcium metabolism. *Handbook of experimental pharmacology*. vol. 83(ed. by Bker, P.F.), pp.441 - 465, Springer Berlin 1988.
 38. Mohammad AR Brunsvold M Bauer R: The strength of associated between systemic postmenopausal osteoporosis and periodontal disease. *Int J Prosthodont* 9: 479 - 483, 1996.
 39. Armstrong WD and Singer L: Fluorine contents of enamel of sound and carious human teeth. *J Dent Res* 42; 133 - 136, 1963.
 40. Ishkawa S: Significance of urinary fluorine content as an index of fluorine body burden. *J Iwate Med Ass* 28; 207 - 222. 1976.
 41. Hall RJ: The spectrophotometric determination of sub - microgram amounts of fluorine in biological specimens. *Analyst* 76 - 83, 1963.
 42. Frant MS and Ross JW: Electrode for sensing fluoride ion activity in solution. *Science* 154; 1553 - 1554, 1966.
 43. 吉田康久 武田吉弘 谷村義久: 尿, 血清中の 弗素 ion 濃度について. *大阪醫大誌* 42; 71 - 85, 1983.
 44. 野原 勝 立身政信 角田文男: 血清中 弗素 ion 濃度と 骨鹽量の 關係について *日衛生誌* 52(口演集);91, 1997.

- Abstract -

The Urinary Fluoride Concentration and Periodontal Condition in Postmenopausal Osteoporotic Women

Young - Jun Kim

Department of Periodontology, College of Dentistry
Chonnam National University, Institute of Dental Science

There were few reports about the fluoride concentration in bone and osteoporotic women. This study was designed to evaluate the relationship between the urinary fluoride concentration and periodontal condition in osteoporotic old women. Twenty-eight postmenopausal women (Test group) and twenty-one premenopausal women (Control group) were examined.

Bone mineral density (BMD) of lumbar spine (L2 - L4) was measured by dual energy X-ray absorptiometry (DEXA). The urine samples were collected at early morning and determined with the help of a fluoride-specific electrode and Tisab-buffered samples.

The results were as follows.

1. The mean urinary fluoride concentration in test and control group showed statistically no difference.

2. The bone mineral density (BMD) of the spine in test group was significantly lower than control group ($p < 0.05$).
3. The significant negative correlation was found between BMD level and age after menopause ($p < 0.001$, $r = -0.526$).
4. The urinary fluoride concentration was not correlated with age, age after menopause and bone mineral density.
5. The urinary fluoride concentration was not correlated with periodontal condition.